13 Jan 2026
Lobe Sciences appointed Nick Karakochuk to Board of Directors to advance governance and capital markets expertise.
6 Jan 2026
Lobe Sciences reported fiscal 2025 results and highlighted strategic transformation following leadership transition.
9 Oct 2025
Lobe Sciences announced improvements to balance sheet.
5 June 2025
Lobe Sciences appointed Yong Yao as Chief Financial Officer to support strategic growth.
14 Apr 2025
Lobe Sciences announced a non-brokered private placement of preferred shares in Cynaptec Pharmaceuticals for US$6M with option for US$20M. Cynaptec will own and develop Conjugated PsilocinTM.
4 Apr 2025
Lobe Sciences provided corporate update regarding recent transactions including issuance of convertible notes and common shares in settlement of accounts payable.
17 Mar 2025
Lobe Sciences announced appointment of Dr. Herman Williams as CEO of Altemia, Inc. Altemia is a medical food for sickle cell disease deficiencies, launching in 2025.
18 Nov 2024
U.S. Patent Office issued notice of allowance for second patent for Conjugated PsilocinTM. Patent covers psilocin mucate compositions and will provide additional coverage.
16 Oct 2024
Lobe Sciences appointed Enclave Capital and Peak Asset Management to raise funds for Conjugated PsilocinTM development through FDA NDA process.
2 Oct 2024
USPTO issued U.S. Patent 12,102,616 titled “Psilocin Mucate” covering compositions, methods of use and production for Conjugated PsilocinTM. Valid until July 2043.